How does Medical Weight Loss work
Protect from excessive heat and light
GLP-1 receptor activation inhibits the activation of hepatic Kupffer cells and infiltrating macrophages, leading to decreased production of pro-inflammatory cytokines such as TNF- and IL-1, thereby attenuating hepatic inflammation ( Preclinical models have shown that GLP-1 analogs suppress hepatic stellate cell activation, the key drivers of fibrogenesis, resulting in reduced collagen deposition and fibrosis ( Clinical trials that investigate dual GLP-1/GIP receptor agonists have presented encouraging evidence for their efficacy and safety in treating MASLD
For example, B12 shots are generally inappropriate for people who have: Allergies to cobalamin, cobalt, or any of the ingredients in B12 injections Taking B12 shots with any of these allergies could lead to a seriouspotentially life-threateningallergic reaction

The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI
A recent study involving tirzepatide suggested postmenopausal women using hormone therapy lost more weight than those not using hormone therapy